We excel in consulting on, designing, and developing large-scale production and processing facilities, implementing Good Manufacturing Practices (GMP) for these operations, and distributing high-quality products internationally. Our portfolio includes several upcoming projects that will launch in 2018—explore our medical cannabis extraction and processing projects for more details.
As we build these facilities, we also establish offtake agreements to secure distribution rights for our products. We collaborate with qualified, vetted farmers and licensed producers to source wholesale medical cannabis and CBD products, including high CBD hemp biomass, high CBD flower, CBD oil, CBD distillate, and CBD isolate for qualified buyers. Additionally, we source large-scale wholesale industrial hemp biomass.
For further insights into our business and international projects, please refer to the information below.
Our Global Focus
Rhizo Sciences is headquartered in Seattle, but the majority of our project work occurs internationally, emphasizing pharmaceutical-grade GMP medical cannabis tailored to the specifications of countries such as Australia, Canada, Israel, and Germany.
As a small company, our success hinges on our agility, innovation, proven solutions, and trusted partnerships.
Milestones
We recently achieved a significant milestone by completing the historic first export of medical cannabis from Africa to Canada, marking one of the first legal imports into Canada.
Read more here.
Pharmaceutical-Grade Medical Cannabis
Rhizo Sciences is dedicated to delivering natural plant medicines that meet pharmaceutical standards for safety, purity, and consistency.
The cannabis industry is evolving rapidly, yet many innovations occur with insufficient attention to compliance, provenance, and quality control. Patients rightly expect their medicines to be tested, safe, and of legitimate origin. Unfortunately, these standards are not met by the black market or gray market medical cannabis, which currently constitutes around 99% of total sales.
Fortunately, similar challenges have been effectively addressed in other industries, including food, herbal medicines, and pharmaceuticals. This focus on compliance and quality control positions the medical cannabis sector as a safe harbor for investors, entrepreneurs, and patients alike.
While much of the global market is inundated with low-quality, poorly regulated cannabis, there is a significant worldwide shortage of legal GMP-certified products.
As a result, the Medical Hemp/Cannabis sector is projected to grow from approximately $10 billion now to $50 billion globally by 2029. Concurrently, the pharmaceutical side of the industry is anticipated to rise from under $1 billion now to $50 billion. Our approach ensures compliance with the necessary standards while also catering to the current medical market in regions like the US and Canada.
Israel continues to be a leader in the medical and pharmaceutical cannabis sectors. We actively consult with new companies looking to enter the legal export market, providing support in facility design, construction, and management. A core aspect of our business is international CBD and cannabis sales, which you can read more about in our outlook on the global legal cannabis market here.
We find the report from Ackrell Capital to be highly useful for investors and clients, and we think you may find it valuable too:
Ackrell Capital 2018 Investor Report
Medical Cannabis Large Scale Projects
Learn more here.
